Drug Interactions in Autoimmune Systemic Lupus Erythematosus (SLE)

Rosyida Awalia  Safitri; William  Sayogo; Yenni  Muflihan; Nurul  Maela; Yuni Wahyuningsih  Setiawan; Sita Fauzia  Rahma

doi:10.55927/mudima.v4i2.8146

Authors

Rosyida Awalia Safitri Fakultas Kesehatan Masyarakat, Universitas Ahmad Dahlan, Yogyakarta
William Sayogo Fakultas Kedokteran, Universitas Ciputra, Surabaya
Yenni Muflihan Ekonomi Manajemen, Sekolah Tinggi Ilmu Manajemen Indonesia Meulaboh, Aceh Barat
Nurul Maela Fakultas Kesehatan Masyarakat, Universitas Ahmad Dahlan, Yogyakarta
Yuni Wahyuningsih Setiawan Fakultas Kesehatan Masyarakat, Universitas Ahmad Dahlan, Yogyakarta
Sita Fauzia Rahma Fakultas Kesehatan Masyarakat, Universitas Ahmad Dahlan, Yogyakarta

DOI:

https://doi.org/10.55927/mudima.v4i2.8146

Keywords:

Autoimmune, SLE, and Drug Interaction

Abstract

One of the factors that influence the success of therapy in autoimmune diseases such as SLE is the interaction of drugs with other active compounds. Several studies have stated that there are drug interactions with drugs or with other active compounds such as herbs which can support therapy or inhibit the effects of drug therapy. This review aims to investigate drug interactions in autoimmune diseases with a focus on systemic lupus erythematosus (SLE). The method used is a systematic review with literature sources in the form of international journals or research articles, and 31 articles met the inclusion criteria. There is evidence of interactions between drugs for the treatment of SLE, such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressants. In addition, results were obtained regarding the interaction of SLE therapy with herbal plants such as Cecendet or Physalis angulata L, horsetail, and fertilizing plants such as Manjakani, Kacip Fatimah, Chlorophyll, and Spirulina as well as interactions between drugs in both SLE therapies with other types of SLE drugs and with herbal medicine, these interactions can support or hinder the therapeutic effect of the drug

References

Balushi, F., et al., (2018). Clinical Pharmacological Management Status of Systemic Lupus Erythematous Population: Situational Analysis. Journal of Rheumatic Diseases and Treatment. Vol 4(1): 1-9.

Bi, C., Matsuda, R., Zhang, C., Isingizwe, Z., Clarke, W., & Hage, D. S. (2017). Studies of Drug Interactions with Alpha1-acid Glycoprotein by Using On-line Immunoextraction and High- Performance Affinity Chromatography. Journal of Chromatography A, 1519, 64-73.

Cellucci, T., Van Mater, H., Graus, F., Muscal, E., Gallentine, W., Klein-Gitelman, M.S., & Dale, R.C. (2020). Clinical Approach to the Diagnosis of Autoimmune Encephalitisin the Pediatric Patient. Neurology-Neuroimmunology Neuroinflammation, 7 (2).

Chen, Y.M., et al., (2019). Combination Immunosuppressant Therapy And Lupus Nephritis Outcome: a Hospital-Based Study. Journal of Lupus. Vol: 1-9.

Cojocaru, M., Cojocaru, I. M., Silosi, I., & Vrabie, C. D. (2011). Manifestations of Systemic Lupus Erythematosus. Maedica, 6(4), 330.

Danve, A., Perry, L., & Deodhar, A. (2014). Use of Belimumab Throughout Pregnancy to Treat Active Systemic Lupus Erythematosus—a Case Report. In Seminars in Arthritis and Rheumatism (Vol. 44, No. 2, pp. 195-197). WB Saunders.

Duran, E., et al. (2021). Spinal and Cerebral Hematoma In Systemic Lupus Erythematosus And Antiphospholipid Syndrome: Is Drug Interaction The Culprit?. Journal of Drug Metabolism and Personalized Therapy. Vol 36(2): 169-172.

Fava A, Petri M. (2019). Systemic Lupus Erythematosus: Diagnosis And Clinical Management. Journal of Autoimmune.96:1-13. doi: 10.1016/j.jaut.2018.11.0. Epub 2018. PMID: 30448290; PMCID: PMC6310637.

Gladstone, D. E., Prestrud, A. A., Pradhan, A., Styler, M. J., Topolsky, D. L., Crilley, P. A & Brodsky, I. (2002). High-dose Cyclophosphamide for Severe Systemic Lupus Erythematosus. Lupus, 11(7), 405-410. Honoré, P.H. 2014. Drug Interactions. Eur J Hosp Pharm. Vol 21(2): 73.

Hu, S. C. S., Yen, F. L., Wang, T. N., Lin, Y.C., Lin, C. L., & Chen, G. S. (2016). Immunosuppressive Medication Use and Risk of Herpes Zoster (HZ) in Patients with Systemic Lupus Erythematosus (SLE): A Nationwide Case-control Study. Journal of the American Academy of Dermatology, 75(1), 49-58.

Husari, K. S., & Dubey, D. (2019). Autoimmune epilepsy. Neurotherapeutics, 16, 685-702

Kamal, M. A., & Jusko, W. J. (2004). Interactions of Prednisolone And Other Immunosuppressants Used In Dual Treatment Of Systemic Lupus Erythematosus In Lymphocyte Proliferation Assays. The Journal of Clinical Pharmacology, 44(9), 1034-1045.

Kim WB, Jerome D, Yeung J. (2017). Diagnosis and management of psoriasis. Can Fam Physician. 63(4):278-285. PMID: 28404701; PMCID: PMC5389757.

Kovvuru, S., Nalleballe, K., Onteddu, S. R., Sharma, R., Jasti, M., Kapoor, N., . & Roy, B. (2021). Immunosuppression in Chronic Autoimmune Neurological Disorders During the COVID-19 Pandemic. Journal of the Neurological Sciences, 420, 117230.

Leelavathi, M., Jamani, N. A., Muhammad, M., Adawiyah, J., & Aziz, N. A. (2010). Drug Reaction with Herbal Supplement: A Possible Case of Drug Induced Lupus Erythematosus. Malaysian Family Physician: the Official Journal of the Academy of Family Physicians of Malaysia, 5(2), 99.

Lehman, T. J., & Onel, K. (2000). Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. The Journal of pediatrics, 136(2), 243-247.

Liang, B., Gardner, D. B., Griswold, D. E., Bugelski, P. J., & Song, X. Y. R. (2006). Anti‐Interleukin‐6 Monoclonal Antibody Inhibits Autoimmune Responses in a Murine Model of Systemic Lupus Erythematosus. Immunology, 119 (3), 296-305.

Lo, M. S., & Tsokos, G. C. (2012). Treatment of systemic lupus erythematosus: new advances in targeted therapy. Annals of the New York Academy of Sciences, 1247(1), 138-152.

Lu, F., Tu, Y., Peng, X., Wang, L., Wang, H., Sun, Z., ... & Hu, Z. (2008). A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus, 17(7).

Maidhof, W., & Hilas, O. (2012). Lupus: an Overview of the Disease and Management Options. Pharmacy and Therapeutics, 37(4), 240.

Medication Adherence in Patients in Treatment For Rheumatoid Arthritis And Systemic Lupus Erythematosus in A University Hospital in Brazil. luciana Resende Prudente, et al, (2016).

Mok, C. C., Tse, S. M., Chan, K. L., & Ho, L.Y. (2018). Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus, 27(5), 722-727.

Nemish, S., et al. 2021. Systemic Lupus Erythematosus Disease: An Overview of the Clinical Approach to Pathogenesis, Diagnosis, and Treatment. Borneo Journal of Pharmacy. Vol 4(2): 91-98.

Obrișcă, B., Sorohan, B., Tuță, L., & Ismail, G. (2021). Advances in Lupus Nephritis Pathogenesis: from Bench to Bedside. International Journal of Molecular Sciences, 22(7), 3766.

Rajaei, E., Shahbazian, N., Rezaeeyan, H., Mohammadi, A. K., Hesam, S., & Zayeri, Z. D. (2019). The Effect of Lupus Disease on The Pregnant Women and Embryos: A Retrospective Study from 2010 to 2014. Clinical Rheumatology, 38, 3211-3215.

Ruiz-Arruza, I., Barbosa, C., Ugarte, A., & Ruiz-Irastorza, G. (2015). Comparison of High Versus Low–Medium Prednisone Doses For The Treatment of Systemic Lupus Erythematosus Patients With High Activity at Diagnosis. Autoimmunity reviews, 14(10), 875-879.

Ruiz-Arruza, I., Ugarte, A., Cabezas- Rodriguez, I., Medina, J. A., Moran, M. A., & Ruiz-Irastorza, G. (2014). Glucocorticoids and Irreversible Damage in Patients with Systemic Lupus Erythematosus. Rheumatology, 53(8),1470-1476.

Ruiz-Irastorza, G., Dueña-Bartolome, L., Dunder, S., Varona, J., Gomez- Carballo, C., Dominguez-Cainzos, J., ... & Lazaro, E. (2021). Eurolupus Cyclophosphamide Plus Repeated Pulses of Methyl-Prednisolone for The Induction Therapy of class III, IV and V Lupus Nephritis. Autoimmunity Reviews, 20(10), 102898.

Setiawati, M., et al., (2021). Drug Use in Systemic Lupus Erythematous (SLE) Outpatients. Journal of Atlantis Press. Vol 33: 451-456.

Sheba, S. H., Setiani, N. A., Sutjiatmo, B., Vikasari, S. N., & Sukandar, E. Y. (2019). Combination Effect of Cecendet (Physalisangulata L.) Extract and Methylprednisolone in Reducing Inflammation and Improving Renal Functions in Pristane-induced Lupus Rat Models. Majalah Kedokteran Bandung, 51(1), 17-24.

Stagaki, E., Mountford, W. K., Lackland, D. T., & Judson, M. A. (2009). The Treatment of Lupus Pernio: Results of 116 Treatment Courses in 54 Patients. Chest, 135(2), 468-476.

Tafti D, Ehsan M, Xixis KL. Multiple Sclerosis. (2022). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; https://www.ncbi.nlm.nih.gov/books/ NBK499849/.

Talukdar, D., Ignacio, D., & Gupta, M. M. (2021). Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications. Coronaviruses, 2(12), 6-12.

Watad, Abdullah, dkk. "Sindrom Autoimun/Inflamasi yang diinduksi oleh adjuvan (ASIA) menunjukkan hubungan penyakit autoimun dan autoinflamasi yang berbeda menurut subtipe adjuvan: Wawasan dari analisis 500 kasus." Imunologi Klinis 203 (2019): 1-8.

Yang, T. H., Tsai-Hung, W., Chang, Y. L., Liao, H. T., Chia-Chen, H., Tsai, C. Y., & Chou, Y. C. (2018). Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus. Clinical Nephrology, 89(4), 277.

Zavada, J., Pešickova, S. S., Ryšava, R., Olejarova, M., Horák, P., Hrnčíř, Z., ... & Tesar, V. (2010). Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: the Cyclofa-Lune Study. Lupus, 19(11), 1281-1289.

Zhang, M., Qi, C., Zha, Y., Chen, J., Luo, P.,Wang, L., ... & Ni, Z. (2019). Leflunomide versus Cyclophosphamide in the Induction Treatment of Proliferative Lupus Nephritis in Chinese Patients: a Randomized Trial. Clinical Rheumatology, 38, 859-867.